Enanta Pharmaceuticals | ENTA - Passifs Courants





Passifs Courants Changement Date
AbbVie USD 42.1B 1.19B 2026-03
Amgen USD 24.96B 534M 2026-03
Anika Therapeutics USD 20.97M 942K 2026-03
Arrowhead Research USD 295.22M 52.2M 2026-03
AstraZeneca USD 32.57B 1.95B 2026-03
BioCryst Pharmaceuticals USD 195.39M 675K 2026-03
Biogen USD 3B 350.5M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Gilead Sciences USD 9.48B 2.34B 2026-03
GlaxoSmithKline GBP 22.43B 1.04B 2026-03
Halozyme Therapeutics USD 363.21M 186.12M 2026-03
Heron Therapeutics USD 90.52M 5.58M 2026-03
Immunic USD 38.36M 7.74M 2026-03
Incyte USD 1.49B 25.52M 2026-03
Insmed USD 361.01M 107.87M 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
J&J USD 57.72B 3.59B 2026-03
Karyopharm Therapeutics USD 92.06M 4.9M 2025-12
Ligand Pharmaceuticals USD 40.67M 3.22M 2026-03
Merck USD 26.94B 1.38B 2026-03
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Novartis USD 31.37B 4.1B 2026-03
Novavax USD 342.46M 117.49M 2026-03
Pfizer USD 34.35B 2.64B 2026-03
PTC Therapeutics USD 923.6M 44.82M 2026-03
Roche Holding CHF 28B 421M 2025-12
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03